|
|
|
|
|
非在研适应症- |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期- |
A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors
The purpose of the study is to evaluate the safety and tolerability of BNA035 in order to determine the maximum tolerated dose (MTD) and Recommended Phase 2 dose (RP2D) and to evaluate the preliminary efficacy for each combination regimen.
100 项与 Binacea Pharma, Inc. 相关的临床结果
0 项与 Binacea Pharma, Inc. 相关的专利(医药)
100 项与 Binacea Pharma, Inc. 相关的药物交易
100 项与 Binacea Pharma, Inc. 相关的转化医学